References
- RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
- Gómez-OutesATerleira-FernándezAILecumberriRSuárez-GeaMLVargas-CastrillónEDirect oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysisThromb Res2014134477478225037495
- ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
- SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
- SchulmanSNew oral anticoagulant agents – general features and outcomes in subsets of patientsThromb Haemost2014111457558224452881
- ProiettiMLipGYHAntidotes to non-vitamin K oral anticoagulants: necessary or not?Expert Opin Pharmacother201516111573157626077323
- GlundSStangierJSchmohlMSafety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialLancet2015386999468069026088268
- PollackCVReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med Overseas Ed20153736511520
- PollackCVReillyPAvan RynJIdarucizumab for dabigatran reversal – full cohort analysisN Engl J Med2017377543144128693366
- SchieleFvan RynJCanadaKA specific antidote for dabigatran: functional and structural characterizationBlood2013121183554356223476049
- PollackCVReillyPABernsteinRDesign and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatranThromb Haemost2015114119820526020620
- RaparelliVProiettiMCangemiRLipGYLaneDABasiliSAdherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulantsThromb Haemost2017117220921827831592
- SiegalDMCurnutteJTConnollySJAndexanet alfa for the reversal of factor Xa inhibitor activityN Engl J Med2015373252413242426559317
- EnriquezALipGYBaranchukAAnticoagulation reversal in the era of the non-vitamin K oral anticoagulantsEuropace201618795596425816811
- EbingerJGrangerCBZhuAChangAHenryTDIdarucizumab since FDA approval: use in the real-worldAm Heart J2017193939429129261
- KirchhofPBenussiSKotechaD2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEur Heart J201637382893296227567408
- NiessnerATamargoJMoraisJReversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on ThrombosisEur Heart J201738221710171626705385
- SalzanoAProiettiMD’AssanteRSaldamarcoLCittadiniAPaladinoFBleeding related to non-vitamin K antagonist oral anticoagulants in emergency department: A “Real-world” snapshot from Southern Italy. On behalf of MIRC-NOAC study groupEur J Intern Med201848e21e2429102387
- TomaselliGFMahaffeyKWCukerA2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral AnticoagulantsJ Am Coll Cardiol201770243042306729203195
- VermaAHaACTRutkaJTVermaSWhat surgeons should know about non-vitamin K oral anticoagulants: A reviewJAMA Surg2018153657729710221
- LevyJHDouketisJWeitzJIReversal agents for non-vitamin K antagonist oral anticoagulantsNat Rev Cardiol201815527328129345686